Mizuho Securities analyst Salim Syed maintained a Buy rating on Assembly Biosciences (ASMB – Research Report) today and set a price target of $14.00. The company’s shares closed last Tuesday at $2.22.
According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.0% and a 35.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.
Assembly Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $9.17.
Based on Assembly Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $23.09 million. In comparison, last year the company had a GAAP net loss of $27.2 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin on October 7, 2005 and is headquartered in Carmel, IN.
Read More on ASMB:
- A Key Insider Loads up on Jefferies Shares
- Reliq Health Technologies, Inc. Announces New Contracts with Four US Pain Management Clinics
- Wilsons Remains a Buy on Telix Pharmaceuticals Ltd. (TLPPF)
- Meta Could Perform Better-Than-Expected in Q2, Says Analyst
- Shaw and Partners Keeps a Buy Rating on Jervois Global Limited (JRVMF)